申请人:Newcastle University Ventures Limited
公开号:US06297250B1
公开(公告)日:2001-10-02
A range of dipyridamole analogues useful for inhibiting transport of nucleosides or purines across cell membranes, thereby to potentiate the activity of various cytotoxic antitumor drugs, is disclosed. These analogues comprise compounds having general structural formula (I) or pharmaceutically acceptable salts thereof; wherein R1 is chloro and R3 is diethanolamino, or R1 and R3 are identical and are selected from allyl, halo, diethanolamino, solketalo and a group having the formula: —O—Rz or —NHRz, Rz being selected from alkyl, hydroxyalkyl, alkoxyalkyl, dialkoxyalkyl and 2-oxo-alkyl wherein the or each alkyl and/or alkoxy moiety has less than six carbon atoms, and R2 and R4 are identical and are selected from piperidino, N-tetrahydroisoquinolyl, and a benzylamino group having structural formula (II) wherein R5 is H, or an optionally substituted alkyl or benzyl group, and R6 and R7 represent H or optional substituents in the aromatic nucleus selected from halo, alkyl, alkoxy, hydroxy, trifluoromethyl, azido, cyano, nitro, carboxyl, carboxylic ester, amino or a substituted amino NRxRy where Rx and Ry each represent hydrogen or alkyl, subject to the provisos that (a) if R1 and R3 are both chloro or diethanolamino, R2 and R4 are not both benzylamino, i.e. R2 and R4 do not correspond to structure II with R5, R6 and R7 each being hydrogen, and (b) if R2 and R4 are both piperidino, R1 and R3 are not both chloro, diethanolamino, solketalo or (2,3-dimethoxy)propoxy
一系列二吡啶酮类似物,用于抑制核苷或嘌呤在细胞膜上的转运,从而增强各种细胞毒性抗肿瘤药物的活性,已被披露。这些类似物包括具有一般结构式(I)或其药用可接受盐的化合物;其中R1为氯,R3为二乙醇胺,或R1和R3相同且选自烯丙基、卤素、二乙醇胺、索尔克塔洛和具有式:—O—Rz或—NHRz的基团,其中Rz选自烷基、羟基烷基、烷氧基烷基、二烷氧基烷基和2-氧代烷基,其中每个烷基和/或烷氧基基团的碳原子数小于六,且R2和R4相同且选自哌啶基、N-四氢异喹啉基和具有结构式(II)的苄氨基团,其中R5为H,或者是一个可选择取代的烷基或苄基团,R6和R7代表H或芳香核中的可选择取代基,选自卤素、烷基、烷氧基、羟基、三氟甲基、叠氮基、氰基、硝基、羧基、羧酸酯、氨基或取代氨基NRxRy,其中Rx和Ry各自代表氢或烷基,但需满足以下条件:(a)如果R1和R3都是氯或二乙醇胺,则R2和R4不能都是苄氨基,即R2和R4不对应于结构II,其中R5、R6和R7各自为氢;(b)如果R2和R4都是哌啶基,则R1和R3不能都是氯、二乙醇胺、索尔克塔洛或(2,3-二甲氧基)丙氧基。